Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Scrambles to Collect Info on AstraZeneca Vaccine Trial Pause, Sticks to 2021 H1 Immunization Goal
The Japanese government on September 9 scrambled to glean information on AstraZeneca’s voluntary trial pause on its COVID-19 vaccine, AZD1222, after it was revealed that all related studies were halted due to an “unexplained illness” that occurred in one subject…
To read the full story
Related Article
- AstraZeneca’s COVID-19 Vaccine Trial Resumes in Japan
October 5, 2020
- AstraZeneca, PMDA Discussing Restart of COVID-19 Vaccine Trial in Japan
September 14, 2020
- Japan to Steadily Collect Info on AstraZeneca Trial Pause: Minister
September 11, 2020
REGULATORY
- Ishin Lawmaker Seeks Full Chuikyo Seat for Industry, but with Fiscal Responsibility
July 22, 2026
- Japan Backs Calquence-Venclexta Regimen for Untreated CLL via Label Updates
July 22, 2026
- Japan OKs Honebuto, Growth Strategy with Patented Drug Market Goals
July 21, 2026
- Takeda’s Oveporexton, Rhythm’s Imcivree Up for Japan Panel Review Aug. 3
July 21, 2026
- Japan’s Immunization Act Bill Set to Clear Diet after Session Extension
July 21, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…